scholarly journals Association between age, deprivation and specific comorbid conditions and the receipt of major surgery in patients with non-small cell lung cancer in England: A population-based study

Thorax ◽  
2018 ◽  
Vol 74 (1) ◽  
pp. 51-59 ◽  
Author(s):  
Aurélien Belot ◽  
Helen Fowler ◽  
Edmund Njeru Njagi ◽  
Miguel-Angel Luque-Fernandez ◽  
Camille Maringe ◽  
...  

IntroductionWe investigated socioeconomic disparities and the role of the main prognostic factors in receiving major surgical treatment in patients with lung cancer in England.MethodsOur study comprised 31 351 patients diagnosed with non-small cell lung cancer in England in 2012. Data from the national population-based cancer registry were linked to Hospital Episode Statistics and National Lung Cancer Audit data to obtain information on stage, performance status and comorbidities, and to identify patients receiving major surgical treatment. To describe the association between prognostic factors and surgery, we performed two different analyses: one using multivariable logistic regression and one estimating cause-specific hazards for death and surgery. In both analyses, we used multiple imputation to deal with missing data.ResultsWe showed strong evidence that the comorbidities ‘congestive heart failure’, ‘cerebrovascular disease’ and ‘chronic obstructive pulmonary disease’ reduced the receipt of surgery in early stage patients. We also observed gender differences and substantial age differences in the receipt of surgery. Despite accounting for sex, age at diagnosis, comorbidities, stage at diagnosis, performance status and indication of having had a PET-CT scan, the socioeconomic differences persisted in both analyses: more deprived people had lower odds and lower rates of receiving surgery in early stage lung cancer.DiscussionComorbidities play an important role in whether patients undergo surgery, but do not completely explain the socioeconomic difference observed in early stage patients. Future work investigating access to and distance from specialist hospitals, as well as patient perceptions and patient choice in receiving surgery, could help disentangle these persistent socioeconomic inequalities.

Author(s):  
Tanzeel Janjua ◽  
Fei Sun ◽  
Katy Clarke ◽  
Pete Dickinson ◽  
Kevin Franks ◽  
...  

Abstract Aim: Centrally located early-stage non-small cell lung cancer in patients who are unfit for surgery are treated with fractionated radiotherapy. We present the outcomes of a moderately hypofractionated accelerated dose regimen of 50 Gy in 15 fractions from a single centre in the UK. Materials and methods: Electronic case notes and radiotherapy records of lung cancer patients treated between January 2014 and December 2016 were retrospectively reviewed. Adult Comorbidity Evaluation-27 score was used to evaluate comorbidities. Mean lung doses and percentage of lung receiving more than 20 Gy were calculated for all patients. Survival outcomes were estimated using Kaplan–Meier curves. Results: Fifty-three patients were included in the study; the median follow-up was 20.2 months. 87% of patients had stage I disease. There was no 30-day post-treatment mortality. Ninety-day mortality rate after radiotherapy was 3.8%. Grade 2 pneumonitis was seen in five patients while no grade 3 or 4 pneumonitis was observed. The median progression-free survival (PFS) and overall survival (OS) were 18.5 months and 28.2 months, respectively. The estimated 1 and 2 years PFS were 62.3% and 41.3%, respectively, and OS were 77.4% and 56.6%, respectively. Worsening performance status was associated with worse survival on cox regression analysis. Disease relapsed in 36% of patients. 7.5% of patients with relapsed disease had infield recurrence. Findings: 50 Gy in 15 fractions radiotherapy for central early-stage lung cancer is a feasible choice that requires further randomised trials.


2019 ◽  
Vol 133 ◽  
pp. S402
Author(s):  
J. Di Muzio ◽  
S. Badellino ◽  
M. Levis ◽  
L. Delsedime ◽  
C. Mantovani ◽  
...  

Lung Cancer ◽  
1999 ◽  
Vol 24 (2) ◽  
pp. 99-106 ◽  
Author(s):  
Yukio Saitoh ◽  
Takehiko Fujisawa ◽  
Mitsutoshi Shiba ◽  
Shigetoshi Yoshida ◽  
Yasuo Sekine ◽  
...  

2010 ◽  
Vol 9 (1) ◽  
pp. 152 ◽  
Author(s):  
Anne-Marie C Dingemans ◽  
Vivian van den Boogaart ◽  
Bettine A Vosse ◽  
Robert-Jan van Suylen ◽  
Arjan W Griffioen ◽  
...  

2013 ◽  
Vol 11 (2) ◽  
pp. 110-122 ◽  
Author(s):  
Paul E. Van Schil ◽  
Bram Balduyck ◽  
Michèle De Waele ◽  
Jeroen M. Hendriks ◽  
Marjan Hertoghs ◽  
...  

2011 ◽  
Vol 2011 ◽  
pp. 1-4 ◽  
Author(s):  
Salah Abbasi ◽  
Ahmed Badheeb

Eleven prognostic factors were retrospectively analyzed in 270 newly diagnosed patients with advanced non-small-cell lung cancer including age, sex, performance status, histology, stage, smoking status, hemoglobin level, forced expiratory volume in one second (FEV1), weight loss >5% in 3 months preceding therapy, number of involved organs, and type of first-line chemotherapy. Response rate was 35.6%, and median survival was 8.2 months (95% CI, 7.8 to 8.7) for the whole group. Age ≤60 years (), (), and the use of platinum/docetaxel () were significantly associated with an improved survival. Histology did not affect outcome in the absence of targeted therapies.


Sign in / Sign up

Export Citation Format

Share Document